论文部分内容阅读
目的观察ＨＰＶ１６，１８Ｅ６在人宫颈癌中的表达并说明Ｅ６单抗的应用价值。方法采用Ｓ－Ｐ免疫组化染色法，检测５０例宫颈鳞状细胞癌，３０例慢性宫颈炎及３０例正常宫颈组织中ＨＰＶ１６，１８ Ｅ６蛋白的表达。结果宫颈癌组中Ｅ６表达的阳性率为７０％（３５／５０），慢性宫颈炎组中Ｅ６阳性率为６．７％（２／３０），４例腹股沟淋巴结转移癌Ｅ６阳性率为７５％（３／４），正常宫颈组中Ｅ６表达均为阴性。Ｅ６的表达与肿瘤的分化程度无关（Ｐ＞０．０５），与肿瘤的良恶性有显著差异（ Ｐ＜ ０．０１）。结论 ＨＰＶ１６，１８感染与宫颈癌病因学密切相关，Ｅ６单抗可作为预测ＨＰＶ１６，１８感染及早期诊断宫颈癌的标记之一。
Objective To observe the expression of HPV16 and 18E6 in human cervical carcinoma and to demonstrate the value of E6 monoclonal antibody. Methods The expressions of HPV16, E6 protein in 50 cases of cervical squamous cell carcinoma, 30 cases of chronic cervicitis and 30 cases of normal cervical tissue were detected by S-P immunohistochemical method. Results The positive rate of E6 expression was 70% (35/50) in cervical cancer group, 6.7% (2/30) in chronic cervicitis group, and 75% in 4 cases of inguinal lymph node metastasis (3/4), E6 expression in normal cervical group were negative. The expression of E6 was not associated with the degree of tumor differentiation (P> 0.05), but significantly different from the benign and malignant tumors (P <0.01). Conclusion HPV16,18 infection is closely related to the etiology of cervical cancer. E6 monoclonal antibody can be used as a marker for HPV16,18 infection and early diagnosis of cervical cancer.